<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36967425</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-742X</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of thrombosis and thrombolysis</Title><ISOAbbreviation>J Thromb Thrombolysis</ISOAbbreviation></Journal><ArticleTitle>Management and outcomes of women with antiphospholipid syndrome during pregnancy.</ArticleTitle><Pagination><StartPage>751</StartPage><EndPage>759</EndPage><MedlinePgn>751-759</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11239-023-02789-8</ELocationID><Abstract><AbstractText>Women with antiphospholipid syndrome (APS) have an increased risk of adverse pregnancy outcomes. To define clinical, serologic, and treatment factors that can predict outcomes in pregnant women with APS. Retrospective cohort study of pregnant women with APS evaluated at a university medical center between January 2006 and August 2021. Demographics, personal and family history of thrombosis, autoimmune disease, antithrombotic use, pregnancy outcomes, maternal and fetal complications were collected. We compared pregnancy outcomes in the presence or absence of lupus anticoagulant (LA), systemic lupus erythematosus (SLE), prior thrombosis or pregnancy losses, and antithrombotic use. There were 169 pregnancies in 50 women; 79 (46.7%) occurred after maternal diagnosis of APS. The most common antithrombotic regimen was aspirin and low molecular weight heparin (LMWH) in 26.6% of pregnancies; 55.0% of all pregnancies and 68.4% of pregnancies post-APS diagnosis resulted in a live birth. In age-adjusted analyses, aspirin plus LMWH regardless of dosage was associated with significantly higher odds of live birth compared with no antithrombotic use (OR&#x2009;=&#x2009;7.5, p&#x2009;&lt;&#x2009;0.001) and compared with aspirin alone (OR&#x2009;=&#x2009;13.2, p&#x2009;=&#x2009;0.026). SLE increased the risk for preterm birth and preeclampsia. A positive LA did not impact the outcomes evaluated and anticardiolipin IgM decreased the risk of pre-eclampsia. The presence of SLE is a significant risk factor for adverse outcomes in pregnant women with APS. Treatment with LMWH and aspirin was superior to aspirin alone. The creation of a global registry may be useful in improving the management of these patients.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Jacqueline J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, New York-Presbyterian Weill Cornell Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adurty</LastName><ForeName>Sanjana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Angelo</LastName><ForeName>Debra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Division of Biostatistics, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeSancho</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0001-9239-5131</Identifier><AffiliationInfo><Affiliation>Division of Hematology-Oncology, Department of Medicine, New York-Presbyterian Weill Cornell Medical Center, New York, NY, USA. mtd2002@med.cornell.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, USA. mtd2002@med.cornell.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1-UL1-TR002384-01</GrantID><Agency>Clinical and Translational Science Center, Weill Cornell Medical College</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Thromb Thrombolysis</MedlineTA><NlmUniqueID>9502018</NlmUniqueID><ISSNLinking>0929-5305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016682">Lupus Coagulation Inhibitor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047928" MajorTopicYN="Y">Premature Birth</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011256" MajorTopicYN="N">Pregnancy Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011225" MajorTopicYN="Y">Pre-Eclampsia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016682" MajorTopicYN="N">Lupus Coagulation Inhibitor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="Y">Pregnancy Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid antibodies</Keyword><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Antithrombotics</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Pregnancy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>26</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36967425</ArticleId><ArticleId IdType="doi">10.1007/s11239-023-02789-8</ArticleId><ArticleId IdType="pii">10.1007/s11239-023-02789-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tektonidou MG, Andreoli L, Limper M et al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296&#x2013;1304. https://doi.org/10.1136/annrheumdis-2019-215213</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215213</ArticleId><ArticleId IdType="pubmed">31092409</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome Longo DL, ed. N Engl J Med. 378(21):2010&#x2013;2021. https://doi.org/10.1056/NEJMra1705454</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1705454</ArticleId><ArticleId IdType="pubmed">29791828</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber K, Sciascia S, de Groot PG et al (2018) Antiphospholipid syndrome. Nat Rev Dis Prim 4(1):17103. https://doi.org/10.1038/nrdp.2017.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.103</ArticleId><ArticleId IdType="pubmed">29321641</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295&#x2013;306. https://doi.org/10.1111/j.1538-7836.2006.01753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockshin MD (2013) Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy. Clin Lab Med 33(2):367&#x2013;376. https://doi.org/10.1016/j.cll.2013.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cll.2013.01.001</ArticleId><ArticleId IdType="pubmed">23702124</ArticleId><ArticleId IdType="pmc">3664954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutteh WH (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174(5):1584&#x2013;1589. https://doi.org/10.1016/s0002-9378(96)70610-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9378(96)70610-5</ArticleId><ArticleId IdType="pubmed">9065133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutteh WH, Ermel LD (1996) A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 35(4):402&#x2013;407. https://doi.org/10.1111/j.1600-0897.1996.tb00501.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0897.1996.tb00501.x</ArticleId><ArticleId IdType="pubmed">8739461</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai R, Cohen H, Dave M, Regan L (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314(7076):253&#x2013;257. https://doi.org/10.1136/bmj.314.7076.253</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.314.7076.253</ArticleId><ArticleId IdType="pubmed">9022487</ArticleId><ArticleId IdType="pmc">2125731</ArticleId></ArticleIdList></Reference><Reference><Citation>Farquharson RG, Quenby S, Greaves M (2002) Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 100(3):408&#x2013;413. https://doi.org/10.1016/s0029-7844(02)02165-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0029-7844(02)02165-8</ArticleId><ArticleId IdType="pubmed">12220757</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskin CA, Spitzer KA, Clark CA et al (2009) Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA trial. J Rheumatol 36(2):279&#x2013;287. https://doi.org/10.3899/jrheum.080763)</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.080763)</ArticleId><ArticleId IdType="pubmed">19208560</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammaritano LR, Bermas BL, Chakravarty EE et al (2020) 2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72(4):529&#x2013;556. https://doi.org/10.1002/art.41191</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41191</ArticleId><ArticleId IdType="pubmed">32090480</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Serrano R, Pons-Estel GJ et al (2015) Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74(6):1011&#x2013;1018. https://doi.org/10.1136/annrheumdis-2013-204838</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204838</ArticleId><ArticleId IdType="pubmed">24464962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockshin MD, Kim M, Laskin CA et al (2012) Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 64(7):2311&#x2013;2318. https://doi.org/10.1002/art.34402</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34402</ArticleId><ArticleId IdType="pubmed">22275304</ArticleId><ArticleId IdType="pmc">3357451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffatti A, Tonello M, Visentin MS et al (2011) Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 50(9):1684&#x2013;1689. https://doi.org/10.1093/rheumatology/ker139</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ker139</ArticleId><ArticleId IdType="pubmed">21652586</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreoli L, Bertsias GK, Agmon-Levin N et al (2017) EULAR recommendations for women&#x2019;s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476&#x2013;485. https://doi.org/10.1136/annrheumdis-2016-209770</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209770</ArticleId><ArticleId IdType="pubmed">27457513</ArticleId></ArticleIdList></Reference><Reference><Citation>Danowski A, de Azevedo MNL, de Souza Papi JA, Petri M (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36(6):1195&#x2013;1199. https://doi.org/10.3899/jrheum.081194</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.081194</ArticleId><ArticleId IdType="pubmed">19447935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffatti A, Calligaro A, Hoxha A et al (2010) Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res (Hoboken) 62(3):302&#x2013;307. https://doi.org/10.1002/acr.20098</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20098</ArticleId><ArticleId IdType="pubmed">20391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese KMJ, Groot PG, Laat B et al (2020) Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 18(11):2828&#x2013;2839. https://doi.org/10.1111/jth.15047</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15047</ArticleId><ArticleId IdType="pubmed">33462974</ArticleId></ArticleIdList></Reference><Reference><Citation>ACOG Committee Opinion No. 579 (2013) Definition of term pregnancy. Obstet Gynecol 122(5):1139&#x2013;1140. https://doi.org/10.1097/01.AOG.0000437385.88715.4a</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.AOG.0000437385.88715.4a</ArticleId></ArticleIdList></Reference><Reference><Citation>Branch DW. IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy. 2017;Identifier: NCT03152058. https://clinicaltrials.gov/ct2/show/NCT03152058</Citation></Reference><Reference><Citation>Jeremic K, Stefanovic A, Dotlic J et al (2015) Neonatal outcome in pregnant patients with antiphospholipid syndrome. J Perinat Med. https://doi.org/10.1515/jpm-2014-0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jpm-2014-0118</ArticleId><ArticleId IdType="pubmed">25324435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wind M, Hendriks M, van Brussel BTJ et al (2021) Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus Sci Med 8:e000472. https://doi.org/10.1136/lupus-2020-000472</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000472</ArticleId><ArticleId IdType="pubmed">33952625</ArticleId><ArticleId IdType="pmc">8103373</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone S, Hunt BJ, Khamashta MA, Bewley SJ, Nelson-Piercy C (2005) Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. J Thromb Haemost 3(2):243&#x2013;245. https://doi.org/10.1111/j.1538-7836.2005.01185.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01185.x</ArticleId><ArticleId IdType="pubmed">15670028</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Nassar K, Carrier M, Ramsay T, Rodger MA (2011) The association between antiphospholipid antibodies and placenta mediated complications: A systematic review and meta-analysis. Thromb Res 128(1):77&#x2013;85. https://doi.org/10.1016/j.thromres.2011.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2011.02.006</ArticleId><ArticleId IdType="pubmed">21420151</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccone G, Berghella V, Maruotti GM et al (2017) Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol 216(5):525.e1-525.e12. https://doi.org/10.1016/j.ajog.2017.01.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2017.01.026</ArticleId><ArticleId IdType="pubmed">28153662</ArticleId></ArticleIdList></Reference><Reference><Citation>Chayoua W, Kelchtermans H, Gris J et al (2020) The (non-)sense of detecting anti-cardiolipin and anti-&#x3b2;2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost 18(1):169&#x2013;179. https://doi.org/10.1111/jth.14633</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14633</ArticleId><ArticleId IdType="pubmed">31519058</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouvier S, Cochery-Nouvellon &#xc9;, Lavigne-Lissalde G et al (2014) Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study. Blood 123(3):404&#x2013;413. https://doi.org/10.1182/blood-2013-08-522623</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-08-522623</ArticleId><ArticleId IdType="pubmed">24200687</ArticleId></ArticleIdList></Reference><Reference><Citation>Empson MB, Lassere M, Craig JC, Scott JR (2005) Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane pregnancy and childbirth group, ed. Cochrane Database of Syst Rev. https://doi.org/10.1002/14651858.CD002859.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002859.pub2</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi T, Gu ZD, Diao Q-zhi (2021) Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. Medicine 100(25):e26264. https://doi.org/10.1097/MD.0000000000026264</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000026264</ArticleId><ArticleId IdType="pubmed">34160390</ArticleId><ArticleId IdType="pmc">8238312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak A, Cheung MWL, Cheak AAC, Ho RCM (2010) Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 49(2):281&#x2013;288. https://doi.org/10.1093/rheumatology/kep373</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep373</ArticleId><ArticleId IdType="pubmed">19965971</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C, Liu Y, Jiang HL (2019) Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med 32(8):1299&#x2013;1311. https://doi.org/10.1080/14767058.2017.1404979</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14767058.2017.1404979</ArticleId><ArticleId IdType="pubmed">29179589</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J (2005) Antiphospholipid antibodies associated with recurrent pregnancy loss: Prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 83(3):684&#x2013;690. https://doi.org/10.1016/j.fertnstert.2004.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fertnstert.2004.11.002</ArticleId><ArticleId IdType="pubmed">15749498</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouda UM, Sayed AM, Abdou AMA, Ramadan DI, Fouda IM, Zaki MM (2011) Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynecol Obstet 112(3):211&#x2013;215. https://doi.org/10.1016/j.ijgo.2010.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijgo.2010.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams VM, Chamley LW, Salmon JE (2017) Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation: pathogenesis of obstetric APS. Arthritis Rheumatol 69(9):1710&#x2013;1721. https://doi.org/10.1002/art.40136</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40136</ArticleId><ArticleId IdType="pubmed">28445926</ArticleId><ArticleId IdType="pmc">5575987</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>